Reuters logo
BRIEF-Proteostasis Therapeutics to prioritize resources on cystic fibrosis R&D
2017年10月31日 / 晚上9点12分 / 20 天前

BRIEF-Proteostasis Therapeutics to prioritize resources on cystic fibrosis R&D

Oct 31 (Reuters) - Proteostasis Therapeutics Inc

* Proteostasis Therapeutics - ‍initiated strategic prioritization to focus resources on research & development of cystic fibrosis programs, among others​

* Proteostasis -‍ as part of the initiative, co is reducing headcount dedicated to research from 46% of total workforce to 34%, by eliminating 13 positions​

* Proteostasis Therapeutics - ‍resulting estimated annual cost savings related to prioritization, including personnel & other operating costs, is about $3 million​

* Proteostasis Therapeutics Inc - ‍expects to incur a one-time cash charge in Q4 of 2017 for severance and other related costs of $0.2 million​

* Proteostasis - ‍restructuring is not anticipated to have operational impact on company’s existing cf programs and its UPR program with Astellas​ Source text for Eikon: Further company coverage:

我们的标准:汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below